

which makes the molecule at least lack IgE binding capacity, and  
 (ii) a Phl p6 molecule having a C-terminal deletion which makes  
 the molecule at least lack IgE binding capacity, wherein the  
 molecules of (i) and (ii) together span the complete sequence of  
 Phl p6.

Please add the following new claims:

15. A hypoallergenic polypeptide consisting of an amino  
 acid sequence of SEQ ID NO: 20.

16. A hypoallergenic immunogenic composition comprising a  
 hypoallergenic polypeptide consisting of an amino acid sequence of  
 SEQ ID NO: 20 and a pharmaceutically acceptable carrier.

17. The composition of claim 6, wherein the molecule having  
 a N-terminal deletion is a polypeptide comprising an amino acid  
 sequence of SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20.

18. A hypoallergenic polypeptide consisting of an amino acid  
 sequence of SEQ ID NO: 21.

19. A hypoallergenic immunogenic composition comprising a  
 hypoallergenic polypeptide consisting of an amino acid sequence of  
 SEQ ID NO: 21 and a pharmaceutically acceptable carrier.

20. The composition of claim 6, wherein the molecule having a C-terminal deletion is a polypeptide comprising an amino acid sequence of SEQ ID NO: 21.

*EJ*  
*Concl*  
21. The composition of claim 6, wherein the molecule having a N-terminal deletion is a polypeptide comprising an amino acid sequence of SEQ ID NO: 18, SEQ ID NO: 19, or SEQ ID NO: 20; and wherein the molecule having a C-terminal deletion is a polypeptide comprising an amino acid sequence of SEQ ID NO: 21.--

---